Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer’s disease
Alzheimer s Research & Therapy2014Vol. 6(4), pp. 45–45
Citations Over TimeTop 10% of 2014 papers
Abstract
We have discovered defined determinants on mis-disordered truncated tau protein which are responsible for tau oligomerisation leading to neurofibrillary degeneration. Antibody DC8E8 reactive with these determinants is able to inhibit tau-tau interaction in vitro and in vivo. DC8E8 is able to discriminate between the healthy and diseased tau proteome, making its epitopes suitable targets, and DC8E8 a suitable candidate molecule, for AD immunotherapy.
Related Papers
- → The future of neurology after the COVID-19 pandemic according to neurology residents(2022)5 cited
- → Quality of life geriatric patients(2008)4 cited
- → Neurosurgery and quality of life in elderly people(2008)1 cited
- → The concept of therapeutic community in a psycho-geriatric day hospital: a case report(2006)
- → A study on stress factors and coping methods among nurses in Ardebil hospitals(2006)